Objective To evaluate the safety, immunogenicity, and efficacy of INO‐3107, a DNA
immunotherapy designed to elicit targeted T‐cell responses against human papillomavirus …

Objectives Pulmonary papillomatosis is a rare but severe manifestation of recurrent
respiratory papillomatosis (RRP). Efficacy data of systemic bevacizumab for pulmonary RRP …

Objective The clinical course of recurrent respiratory papillomatosis (RRP) varies from
spontaneous remission to severe airway obstruction with wide variability in recurrence …

Objectives To characterize treatment response of recurrent respiratory papillomatosis (RRP)
including adult-onset RRP (AORRP) and juvenile-onset RRP (JORRP) to systemic …

Recurrent respiratory papillomatosis (RRP) is a benign disease of the upper aerodigestive
tract caused by human papillomavirus (HPV) types 6 and 11. The clinical course is …

Objectives Medical therapies to limit disease recurrence are critically needed for recurrent
respiratory papillomatosis (RRP). Systemic bevacizumab is emerging as an exciting …

Recurrent respiratory papillomatosis is strictly connected with human papillomavirus (HPV)
infection of the epithelium of the upper respiratory tract. The main treatment of lesions …

Recurrent respiratory papillomatosis (RRP) is the most common benign pediatric laryngeal
neoplasm. Various adjuvant medical therapies have failed to reliably decrease surgical …

Background The national immunization program in the Netherlands currently uses the
bivalent human papillomavirus (HPV) vaccine, targeting HPV genotypes 16 and 18. It is not …

Background Tracheostomy is a vital therapy for juvenile-onset recurrent respiratory
papillomatosis (JORRP) to maintain an adequate airway in an emergency, yet the …